Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2531562 | 0.91 | DRD2 (0.41) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL5379982 | 0.87 | AKR1B10 (0.47) | S1PR2PKMCCR1OPRM1OPRD1 | |
| SCHEMBL5381232 | 0.87 | CCR1 (0.50) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL5380104 | 0.87 | CCR1 (0.50) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL5367987 | 0.87 | POLB (0.42) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL3860368 | 0.84 | OPRL1 (0.46) | DRD2DRD4DRD3S1PR2OPRM1 | |
| SCHEMBL5375986 | 0.84 | CCR1 (0.42) | DRD2DRD4DRD3S1PR2PKM | |
| SCHEMBL2534655 | 0.84 | CCR2 (0.40) | DRD2MEN1KMT2A | |
| SCHEMBL16874827 | 0.83 | KDM4E (0.51) | MEN1KMT2AS1PR2CCR1KDM4E | |
| SCHEMBL5169875 | 0.83 | SLC6A4 (0.39) | DRD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963268-B1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080269286-A1 | Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269286-A1 | Disubstituted Phenylpiperidines as Modulators of Cortical Catecholaminergic Neurotransmission | SLC6A2, SLC18A2, PNMT | DRD2 27/4885DRD4 87/4885DRD3 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.